Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA


The tolerance and diagnostic efficacy of a new nonionic, intravenous MRI contrast medium, gadodiamide injection (Omniscan®) are reported and compared with those of gadolinium-DOTA after completion of a double-blind, randomized, parallel study in 60 patients using a dose of 0.1 mmol/kg. Two patients were excluded from the statistical analysis after trial entrance since no contrast medium was injected. The indications for the MRI examination were known or suspected CNS lesions. Vital signs, chemical and haematological parameters were monitored. No significant abnormalities were observed, confirming the excellent tolerance of both contrast media. The usefulness of gadolinium-containing contrast media was again documented, since in 8.6% (5/58) of the patients the lesion(s) could be seen only after injection. Contrast enhancement was seen in 87.8% (43/49) of the patients with abnormal findings, and provided additional diagnostic information in 24.5% (12/49). Lack of contrast enhancement in 12.2% (6/49) of patients with abnormal findings was a significant negative finding.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in to check access.


  1. 1.

    Roman-Goldstein SM, Barnett PA, McCormick CI, Ball MJ, Ramsey F, Neuwelt EA (1991) Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings. AJNR 12:885–890

  2. 2.

    Weinmann HJ, Brasch RC, Press WR, Wesbey GE (1984) Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR 142:619–624

  3. 3.

    Laniado M, Weinmann HJ, Schörner W, Felix R, Speck U (1984) First use of gadolinium-DTPA/dimeglumine in man. Physiol Chem Phys Med NMR 16:157–165

  4. 4.

    Sze G (1990) New applications of MR contrast agents in neuroradiology. Neuroradiology 32:421–438

  5. 5.

    Schörner W, Laniado M, Niendorf HP, Schubert C, Felix R (1986) Time-dependent changes in image contrast in brain tumors after gadolinium-DTPA. AJNR 7:1013–1020

  6. 6.

    Parizel PM, Degryse HR, Ghevens J, et al (1989) Gadolinium-DOTA-enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 13:378

  7. 7.

    Post MJD, Sze G, Quencer RN, et al (1990) Gadolinium-enhanced MR in spinal infection. J Comput Assist Tomogr 14:721–729

  8. 8.

    Ross JS, Modic MT, Masaryk TJ, et al (1989) Assessment of extradural degenerative disease with Gd-DTPA-enhanced MR imaging: correlation with surgical and pathologic findings. AJNR 10:1243–1249

  9. 9.

    Crain MR, Yuh WTC, Greene GM, Loes DJ, Ryals TJ, Sato Y, Hart MN (1991) Cerebral ischemia: evaluation with contrast-enhanced MR imaging. AJR 157:575–583

  10. 10.

    Parizel PM, Balériaux D, Rodesch G, et al (1989) Gadolinium-DTPA-enhanced MR imaging of spinal tumors. AJNR 10:249–258

  11. 11.

    Valk J (1988) Gd-DTPA in MR of spinal lesions. AJR 150:1163–1168

  12. 12.

    Chamberlain MC, Sandy AD, Press GA (1991) Spinal cord tumors: gadolinium-DTPA-enhanced MR imaging. Neuroradiology 33:469–474

  13. 13.

    Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W (1991) Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 22:222–228

  14. 14.

    Goldstein HA, Kashanian FK, Blumetti RF, Holyoak WL, Hugo FP, Blumenfield DM (1990) Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 174:17–23

  15. 15.

    Salonen OLM (1990) Case of anaphylaxis and four cases of allergic reaction following Gd-DTPA administration. J Comput Assist Tomogr 14:912–913

  16. 16.

    Tishler S, Hoffman JC (1990) Anaphylactoid reactions to IV gadopentetate dimeglumine. AJNR 11:1167

  17. 17.

    Harbury OL (1991) Generalized seizure after IV administration of gadopentetate dimeglumine. AJNR 12:666

  18. 18.

    Chang CA, Sieving PF, Watson AD, Dewey TM, Karpishin TB, Raymond KN, et al (1992) Ionic versus nonionic MR imaging contrast media: operational definitions. J Magn Reson Imaging 2:95–98

  19. 19.

    O'Toole M, Van Wagoner M, Broschart JL, Prasad R, Leese PT, Quay SC (1989) Non-ionic MRI contrast agents: a phase I clinical trial of the safety and tolerance of S 041 injection. Magn Reson Imaging 7 [Suppl 1]:134

  20. 20.

    Kaplan GD, Aisen AM, Aravapalli SR (1991) Preliminary clinical trial of gadodiamide injection: a new nonionic gadolinium contrast agent for MR imaging. J Magn Reson Imaging 1:57–62

  21. 21.

    Van Wagoner M, O'Toole M, Worah D, Leese PT, Quay SC (1991) A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 26:980–986

  22. 22.

    Greco A, McNamara MT, Lanthiez P, Quay SC, Michelozzi G (1990) Gadodiamide injection: nonionic gadolinium chelate for MR imaging of the brain and spine — phase II–III clinical trial. Radiology 176:451–456

  23. 23.

    Sze G, Brant-Zawadzki M, Haughton VM, et al (1991) Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181:693–699

Download references

Author information

Correspondence to D. Balériaux.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Balériaux, D., Matos, C. & De Greef, D. Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 35, 490–494 (1993).

Download citation

Key words

  • Magnetic resonance imaging
  • Brain
  • Spine
  • Contrast enhancement